Ocriplasmin Approved by FDA to Treat Vitreomacular Adhesion

July 31, 2012

We’ve previously monitored developments with respect to ThromboGenics ocriplasmin for treatment of vitreomacular adhesion.

Last Thursday, an FDA panel recommended ThromboGenics NV’s ocriplasmin as a treatment for vitreomacular adhesion. The panel concluded that the injectable drug, marketed under the brand name Jetrea, helped enough people in clinical trials to warrant a favorable review, despite evidence of adverse effects including eye pain, swelling and blurred vision.

Click here for the full release (PDF).




Jump down to form below to submit your own comments

Comments are closed.